SG11202106251UA - Bifunctional anti-pd-1/sirpa molecule - Google Patents

Bifunctional anti-pd-1/sirpa molecule

Info

Publication number
SG11202106251UA
SG11202106251UA SG11202106251UA SG11202106251UA SG11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA
Authority
SG
Singapore
Prior art keywords
sirpa
molecule
bifunctional anti
bifunctional
sirpa molecule
Prior art date
Application number
SG11202106251UA
Inventor
Nicolas Poirier
Caroline Mary
Aurore Morello
Kevin Biteau
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of SG11202106251UA publication Critical patent/SG11202106251UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202106251UA 2018-12-21 2019-12-17 Bifunctional anti-pd-1/sirpa molecule SG11202106251UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306810 2018-12-21
PCT/EP2019/085785 WO2020127373A1 (en) 2018-12-21 2019-12-17 Bifunctional anti-pd-1/sirpa molecule

Publications (1)

Publication Number Publication Date
SG11202106251UA true SG11202106251UA (en) 2021-07-29

Family

ID=65628505

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106251UA SG11202106251UA (en) 2018-12-21 2019-12-17 Bifunctional anti-pd-1/sirpa molecule

Country Status (14)

Country Link
US (1) US20220056135A1 (en)
EP (1) EP3898676A1 (en)
JP (1) JP2022514698A (en)
KR (1) KR20210107062A (en)
CN (1) CN113574067A (en)
AU (1) AU2019409805A1 (en)
BR (1) BR112021012040A2 (en)
CA (1) CA3122914A1 (en)
CL (1) CL2021001627A1 (en)
EA (1) EA202191763A1 (en)
IL (1) IL283992A (en)
MX (1) MX2021007274A (en)
SG (1) SG11202106251UA (en)
WO (1) WO2020127373A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551661A1 (en) 2016-12-09 2019-10-16 Alector LLC Anti-sirp-alpha antibodies and methods of use thereof
AU2018213890B2 (en) 2017-01-25 2023-07-20 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
PE20210342A1 (en) 2018-05-25 2021-02-23 Alector Llc ANTI-SIRPA ANTIBODIES AND METHODS OF USING THEM
CA3122526C (en) 2018-12-21 2023-01-03 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
WO2020127369A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
CN114805592A (en) * 2022-05-13 2022-07-29 南京吉盛澳玛生物医药有限公司 Design, preparation and application of trispecific antibody
WO2024028386A1 (en) * 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN115386550A (en) * 2022-10-26 2022-11-25 成都诺医德医学检验实验室有限公司 Method for evaluating anticancer effectiveness of immune cells
CN118591566A (en) * 2022-11-07 2024-09-03 北京伟德杰生物科技有限公司 Bifunctional fusion proteins and uses thereof
CN115814091B (en) * 2022-12-19 2024-08-09 中山大学 Use of CD43 inhibitor in preparation of anti-colorectal tumor drugs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5275285A (en) 1992-12-30 1994-01-04 Clegg Industries Business card holder with sound generating microchip
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
PT1366067E (en) 2001-03-07 2012-11-29 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
BRPI0508761A (en) 2004-03-31 2007-08-14 Genentech Inc humanized antibody, composition comprising a humanized antibody, isolated nucleic acid, vector, host cell, humanized antibody production process, tgf-beta dysfunction treatment method, tgf-beta detection method, manufactured article and method of treating cancer
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2861307C (en) 2012-01-17 2021-05-25 The Board Of Trustees Of The Leland Stanford Junior University High affinity sirp-alpha reagents
CN105683217B (en) 2013-05-31 2019-12-10 索伦托治疗有限公司 Antigen binding proteins that bind to PD-1
AU2015247358B2 (en) 2014-04-18 2020-02-27 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
CN106535914B (en) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-alpha variant constructs and uses thereof
SG11201701189TA (en) 2014-08-15 2017-03-30 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
CN108976300B (en) 2015-07-30 2023-04-14 宏观基因有限公司 PD-1 binding molecules and methods of use thereof
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
CA3011815A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
EP4070812A1 (en) * 2016-01-21 2022-10-12 The Board of Trustees of the Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
WO2017132825A1 (en) 2016-02-02 2017-08-10 华为技术有限公司 Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN107459578B (en) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 Difunctional fusion protein targeting CD47 and PD-L1
IL265179B2 (en) 2016-09-14 2024-02-01 Abbvie Biotherapeutics Inc Anti-pd-1(cd279) antibodies
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EA201891882A1 (en) * 2017-02-17 2019-07-31 Осе Иммьюнотерапьютикс NEW ANTIBODIES TO SIRPa AND OPTIONS OF THEIR THERAPEUTIC APPLICATION
CN108623689B (en) * 2017-03-15 2020-10-16 宜明昂科生物医药技术（上海）有限公司 Novel recombinant bifunctional fusion protein, preparation method and application thereof
US20200157179A1 (en) * 2017-03-28 2020-05-21 Trillium Therapeutics Inc. Cd47 blockade therapy
JP7160833B2 (en) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． anti-SIRP alpha antibody
CN111372590A (en) 2017-09-23 2020-07-03 纪念斯隆-凯特林癌症中心 A33 antibody compositions and methods of using the same in radioimmunotherapy
JP6961090B2 (en) * 2017-12-08 2021-11-05 ハンクス バイオファーマシューティクス，インコーポレイテッド Anti-PD-1 / CD47 bispecific antibody and its application
CA3096764A1 (en) 2018-03-05 2019-09-12 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
WO2020127369A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1

Also Published As

Publication number Publication date
CN113574067A (en) 2021-10-29
IL283992A (en) 2021-07-29
KR20210107062A (en) 2021-08-31
CL2021001627A1 (en) 2022-01-07
JP2022514698A (en) 2022-02-14
US20220056135A1 (en) 2022-02-24
EA202191763A1 (en) 2022-03-10
MX2021007274A (en) 2021-07-15
AU2019409805A1 (en) 2021-07-22
EP3898676A1 (en) 2021-10-27
WO2020127373A1 (en) 2020-06-25
BR112021012040A2 (en) 2021-11-03
CA3122914A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
IL283992A (en) Bifunctional anti-pd-1/sirpa molecule
IL284052A (en) Bifunctional molecule directed against human pd-1
IL284002A (en) Bifunctional anti-pd-1/il-7 molecule
FR3049459B1 (en) BIPHASE CLEANING COMPOSITION
IL271790A (en) Chromatography
IL272006A (en) Bifunctional compounds
GB201708113D0 (en) Materials
GB201803983D0 (en) Materials
IL281526A (en) Rail-switching unit
GB2561947B (en) Tissue-adhesive materials
EP3756002C0 (en) Liquid chromatography technique
EP3594305A4 (en) Oil-repellent composition
IL281949A (en) Small molecule menin inhibitors
IL276999A (en) Breastshield unit
EP3563970A4 (en) Rotary clamp
IL269402A (en) Liquid biopsy for cfrna
IL282230A (en) Chimeric molecules
GB201801652D0 (en) Materials
GB2571544B (en) Sectioning macrotome
GB201708013D0 (en) Materials
GB201700390D0 (en) Compounds for enhancing autophagy
EP3873480C0 (en) Anti-acne composition
SG11202106183TA (en) Waterborne basecoat composition
SG11202011746UA (en) Application container
PL3819231T3 (en) Application container